KMA Holding, Inc.

KMA Holding, Inc., through its subsidiaries, manufactures human and pet home medical test kits and emergency response mobile hospital units in the United States. The company focuses on the detection of various illnesses, such as cancer, through the analysis of blood, saliva, urine, hair, and other substances. It offers home screening medical detection test kits for drugs of abuse, sexually transmitted diseases, infectious deceases, tumor marker, and fertility. The company also provides pet home medical test kits for cancer, diabetics, and lime diseases. In addition, it offers emergency medical response mobile hospital units, which enable the provision of temporary emergency life support, and medical and pharmaceutical products and services; and communication via secured wireless technology. The company was formerly known as Macada Holding, Inc. and changed its name to KMA Holding, Inc. in March 2011. KMA Holding, Inc. was founded in 2000 and is based in Pompano Beach, Florida.

KMA Holding, Inc. trades as MCDA on OTC. The company is classified in Healthcare / Medical - Instruments & Supplies and reports in USD.

The current profile places the business in Medical - Instruments & Supplies. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

KMA Holding, Inc. can be compared against peers such as BrainsWay Ltd., CYBERDYNE Inc., China Evergrande New Energy Vehicle Group Limited, Genfit S.A., Medical Facilities Corporation, M1 Kliniken AG.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $4.24M, beta of -3.14, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

MCDA currently shows total debt of N/A and beta of -3.14. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.kmaholding.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.